Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T14:10:55.144Z.
Calculation as of: 2026-10-06T14:10:55.144Z.
Quote observation: 2026-10-06T14:10:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6a2f90c369cc2bba861e7882df5fb589e6a534c6c6a3ec3aca589af2a274c9b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Anteris Technologies Global Corp.
Market Cap
$716.11M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$715.49M
Free Cash Flow Yield
45.88%
TTM Avg
23.39%
3Y Avg
20.43%
5Y Avg
18.16%
Market Cap
$715.02M
Free Cash Flow Yield
N/A
TTM Avg
23.05%
3Y Avg
23.09%
5Y Avg
23.09%
Market Cap
$719.62M
Free Cash Flow Yield
N/A
TTM Avg
5.55%
3Y Avg
5.46%
5Y Avg
5.46%
Market Cap
$740.03M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$745.42M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$683.14M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$764.21M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$762.81M
Free Cash Flow Yield
N/A
TTM Avg
3.52%
3Y Avg
2.41%
5Y Avg
1.72%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $716.11M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $715.49M | 45.88% | 23.39% | 20.43% | 18.16% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $715.02M | N/A | 23.05% | 23.09% | 23.09% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $719.62M | N/A | 5.55% | 5.46% | 5.46% |
| Candel Therapeutics, Inc. (CADL)vs › | $740.03M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $745.42M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $683.14M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $764.21M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $762.81M | N/A | 3.52% | 2.41% | 1.72% |
| Helus Pharma Inc. (HELP)vs › | $658.52M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
